Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms with demonstrated profound efficacy (onset duration and/or prolonged treatment duration) in humans for the treatment of mental health disorders.
PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug discovery.
Voyager Therapeutics is unlocking the potential of adeno-associated virus gene therapy to treat a range of neurological disorders, broadening the therapeutic window while ensuring efficacy and safety.
Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty electrical activity in the brain.
Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.
EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company’s state-of-the-art, zebrafish-based platform technology. EraCal is raising a series A to generate human proof-of-concept data for Era-379 and expanding its portfolio through co-development partnerships.
By coupling Twist Bioscience’s DNA-writing technology with expertise in antibody engineering, Twist Biopharma is helping companies accelerate the development of new biologics.
Amyl Therapeutics is developing a novel treatment for clearing misfolded proteins that aggregate into fibrils to form amyloid plaques that bind to organs, causing neurodegenerative diseases and other systemic conditions.
Orthogon Therapeutics is developing first-in-class anti-infective small molecule drugs using biophysics- and structure-based drug design to optimize compounds that target difficult-to-drug proteins. The company’s initial focus is on treating BK and JC polyomavirus infections in transplant patients.
The biotech company’s federated platform has enabled it to accumulate some high-profile pharma and drug discovery partnerships in its five-year history.
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.
Chimeron Bio aims to transform RNA therapy with its novel nanoparticle technology by developing new vaccines and therapies based on self-amplifying RNA for the treatment of infectious diseases, oncology and rare genetic disorders.
Building on its history of successful collaborations, the global business unit at Sanofi responsible for vaccines is seeking partners with a common drive for excellence and pursuit of innovation.
Membrane lipids have long been neglected as therapeutic targets, but Laurent Pharmaceuticals is breaking new ground with LAU-7b, a first-in-class membrane-lipid modulator for the treatment of coronavirus infection.
COVID-19 reinforced the value of infectious disease vaccines and medicines. GSK works to realise that value by putting research and development at the heart of innovation, harnessing immune science, human genetics, and advanced technologies to deliver new and specialty products.
Partnering with like-minded, focused innovators provides AstraZeneca with access to cutting-edge science and opportunities in oncology, with recent deals and an evolving partnering strategy driving its industry-leading marketed oncology portfolio.
BenchSci is on a mission to increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence (AI).
